Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.

CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.

Search Results

1277 Results

969 – The Impact of Rifampin Drug Interactions on TPT Completion and Safety Using High-Dose vs Standard

Background Tuberculosis preventive treatment (TPT) has been recognized by the World Health Organization as a critical intervention to eliminate tuberculosis. Rifampin TPT is critical to this goal, given high completion rates, short treatment lengths, and low side-effects. However, rifampin treatment has limitations by drug-drug interactions (DDI) with multiple medications   Methods A post-hoc data analysis…

971 – Patient and Provider Preferences for Long-Acting Tuberculosis Preventive Therapy

Background Tuberculosis preventive therapy (TPT) is a key intervention for tuberculosis (TB) elimination. The introduction of long acting (LA) TPT has the potential to enhance adherence, minimize treatment interruptions, improve completion rates, and extend protection against tuberculosis. Methods We conducted a cross-sectional in-person survey among patients in two high-burden TB countries to evaluate preferences, and concerns…

970 – Weekly Rifapentine and Isoniazid (3HP) vs Isoniazid Preventive Therapy (6H) Among People With HIV

Background People with HIV (PHIV) have a 30% lifetime risk of developing tuberculosis (TB) disease, which TB preventive therapy (TPT) reduces by 60%. Six-month daily isoniazid (6H) regimens are challenged by non-adherence and suboptimal completion. Shorter regimens such as 3-month weekly rifapentine and isoniazid (3HP) were introduced in Kenya in October 2022. There is a…

935 – Long COVID Associates With Slow Viral Clearance and Viral Rebound During Acute SARS-CoV-2 Infection

Background SARS-CoV-2-host dynamics during acute infection appear to be important in the development of long COVID. However, prior studies were limited by cohort size and infrequent sampling during acute infection, and no study has addressed the association of viral rebound and long COVID. Here we present data from a large cohort study that tested people…

972 – Effect of Tuberculosis Preventive Therapy on Mtb-Specific T-Cell Profile in the A5279/BRIEF TB Trial

Background People with HIV (PWH) have impaired Mycobacterium tuberculosis (Mtb)-specific T cell responses, making induction of effective immunity challenging. Whether TB preventive therapy (TPT) modifies Mtb-specific T cell profile in PWH is unknown. We interrogated Mtb antigen-specific T cell responses in PWH with latent TB infection (LTBI) pre- and post-TPT within the ACTG A5279 clinical…

936 – Preserved Adrenal Function in People With Long COVID

Background Low serum cortisol has been associated with long COVID (LC) in some but not all studies. However, these studies examined untimed cortisol levels, which may not adequately assess adrenal function. Here we assessed untimed, timed, and stimulated cortisol levels and tested their association with LC. Methods Untimed total cortisol levels were quantified in 711…

812 – Heart Failure Among People With HIV: Prescription of Guideline-Directed Medical Therapy

Background People with HIV (PWH) have an increased risk of heart failure (HF), and HF outcomes among PWH are worse than in persons without HIV. Guideline-directed medical therapy (GDMT) is the cornerstone of HF management but is often suboptimally prescribed. Despite poor HF outcomes in PWH, little is known about GDMT prescription among PWH with…

813 – Mitochondrial Haplogroups and Left Ventricular Dysfunction in People Living With and Without HIV

Background Mitochondrial dysfunction is implicated in the development of heart failure, which is more common in people with HIV (PWH) than those without HIV (PWoH). Whether genetic variations in mitochondrial DNA (mtDNA) are related to cardiac dysfunction, specifically left ventricular diastolic dysfunction (LVDD), has not been well studied in PWH. Methods We included men from…

815 – Readmission Risk for Adults With HIV Hospitalized for Heart Failure or Acute Myocardial Infarction

Background People with HIV (PWH) have a higher incidence of cardiovascular disease, including heart failure (HF) and acute myocardial infarction (AMI) than people without HIV (PWoH). In the general population, 30-day readmissions following hospitalizations for HF and AMI are common, and reducing these readmissions is a national quality of care priority. This study compares the 30-day…

814 – Physician-Confirmed Incident Heart Failure Phenotypes and Etiologies Within CNICS

Background People with HIV (PWH) have elevated risk for heart failure (HF). However, limited multi-center data exist on presentations and etiologies of HIV-associated HF. Methods We adjudicated incident HF events occurring between January 1, 2010 and December 31, 2023 at University of Washington (UW) and University of Alabama-Birmingham (UAB), which are two centers within the…